Nephropathy in Patients with Type 2 Diabetes

A 60-year-old man with recently diagnosed type 2 diabetes mellitus has a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter), and a dipstick test shows proteinuria (++). His blood pressure is 150/90 mm Hg. He smokes half a pack of cigarettes daily. What can be done to reduce the risk of progressive renal disease?

[1]  P. Raskin,et al.  Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.

[2]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[3]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[4]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[5]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[6]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[7]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[8]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[9]  W. Anderson,et al.  Proceedings of the Meeting ‘Profiling dialysis in the year 2000’. Introduction—Prof. Vittorio Bonomini, University of Bologna , 1996 .

[10]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[11]  D. Marrero,et al.  Promoting behavioral science research in diabetes. , 2001, Diabetes care.

[12]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[13]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  B. Kasiske,et al.  Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.

[15]  P. Weidmann,et al.  Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. , 1995, Nephrology, Dialysis and Transplantation.

[16]  G. Bakris.  Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. , 1991, American Journal of Hypertension.

[17]  J. Vienken,et al.  Membranes for dialysis. , 1994, Casopis lekaru ceskych.

[18]  G. Remuzzi,et al.  Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.

[19]  H. Parving,et al.  Evolving strategies for renoprotection: diabetic nephropathy , 2001, Current opinion in nephrology and hypertension.

[20]  R. Hiatt,et al.  Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population. , 1989, Nephron.

[21]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[22]  G. Remuzzi,et al.  The diagnosis of renal involvement in non‐insulin-dependent diabetes mellitus , 1997, Current opinion in nephrology and hypertension.

[23]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[24]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[25]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[26]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[27]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[28]  G. Blohmé,et al.  The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[30]  E. Ritz,et al.  Smoking: a factor promoting onset and progression of diabetic nephropathy. , 2000, Diabetes & metabolism.

[31]  G. Bakris,et al.  Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. , 1998, Kidney international.

[32]  G. Remuzzi,et al.  Progression, remission, regression of chronic renal diseases , 2001, The Lancet.